Zaleplon

Zaleplon
Clinical data
Trade names	Sonata, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601251
License data	US DailyMed: Zaleplon;
Addiction; liability	Moderate
Routes of; administration	By mouth
Drug class	nonbenzodiazepine
ATC code	N05CF03 (WHO) ;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); UK: Class C; US: Schedule IV;
Pharmacokinetic data
Bioavailability	30% (oral)
Metabolism	Liver aldehyde oxidase (91%), CYP3A4 (9%)
Metabolites	No active metabolites
Onset of action	10 to 30 minutes
Elimination half-life	1 hr
Duration of action	Approximately 4 to 6 hours
Excretion	Kidney
Identifiers
	IUPAC name N-(3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl)phenyl)-N-ethylacetamide;
CAS Number	151319-34-5 ;
PubChem CID	5719;
IUPHAR/BPS	4345;
DrugBank	DB00962 ;
ChemSpider	5517 ;
UNII	S62U433RMH;
KEGG	D00530 ;
ChEBI	CHEBI:10102 ;
ChEMBL	ChEMBL1521 ;
CompTox Dashboard (EPA)	DTXSID5023748 ;
ECHA InfoCard	100.126.674
Chemical and physical data
Formula	C17H15N5O
Molar mass	305.341 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1;
	InChI InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3 ; Key:HUNXMJYCHXQEGX-UHFFFAOYSA-N ;
	(verify)

Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.